@article{e9fc0867c4f2441eae2a039b6cfca9cb,
title = "Oncoproteomic profiling of AML: moving beyond genomics",
keywords = "AML, FLT3 inhibitor, drug resistance, leukemia, oncoproteomics, phosphoproteomics, proteogenomics",
author = "Joshi, {Sunil K.} and Tognon, {Cristina E.} and Druker, {Brian J.} and Rodland, {Karin D.}",
note = "Funding Information: This work was supported by the National Cancer Institute{\textquoteright}s Office of Cancer Clinical Proteomics Research (Clinical Proteomic Tumor Analysis Consortium [CPTAC]) under U01CA271412 awarded to CET, BJD, and KDR. SKJ is supported by the ARCS Scholar Foundation, The Paul & Daisy Soros Fellowship, and the NCI (F30CA239335). We apologize to all the authors whose work could not be included in this editorial owing to space constraints.",
year = "2022",
doi = "10.1080/14789450.2023.2176757",
language = "English (US)",
volume = "19",
pages = "283--287",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor and Francis Ltd.",
number = "7-12",
}